Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

leading to severe symptoms and, in some cases, hospitalization,” said Stéphane Bancel, CEO of Moderna, in a statement last fall. “By advancing our investigational norovirus vaccine into a ...

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical ... Fever or headaches may also occur. Symptoms usually develop 12 to 48 hours after being exposed, and recovery ...

Be it from tap water on a vacation, some dodgy chicken, or something the kids have brought home from school, we've almost all ...

Since 2023, Moderna has been studying a vaccine to keep people from getting infected with H5N1, which has been decimating flocks of birds throughout the nation. It has also run rampant in herds of ...

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine ...

Moderna intends to use the above-mentioned funds to support the late-stage development of mRNA-1018, its investigational pandemic influenza vaccine against H5 and H7 avian influenza viruses.

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.